Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01942395
Other study ID # HUM00052649
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 18, 2012
Est. completion date February 16, 2016

Study information

Verified date June 2018
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine how dietary changes affect the heart and blood vessels in patients with hypertension (high blod pressure) who have a condition called 'heart failure with preserved ejection fraction" (HFPEF). This condition is also known as "diastolic heart failure" or "heart failure with normal ejection fraction", and occurs even though the heart's pumping function is normal.


Description:

In an earlier study, the investigators found that patients with HFPEF who ate a special diet for three weeks had improved blood pressure control and lower levels of blood chemicals that may damage the heart and blood vessels. The eating plan in the study was based on the DASH diet, also known as the Dietary Approaches to Stop Hypertension diet. This plan is rich in fruits, vegetables, and low-fat dairy, and is recommended to decrease blood pressure in patients with hypertension. Current medical guidelines also recommend that both patients with hypertension and those with heart failure should decrease their dietary salt intake.

The diets that patients will eat in this study are the DASH/sodium-restricted (DASH/SRD) diet as well as a control diet based on the average reported diet collected using Food Frequency Questionnaires during our pilot study. Patients will be randomized to one diet for three weeks and then crossover to the other diet for three weeks. Patients will then be asked to eat the DASH/sodium-restricted diet on their own at home with dietary support for an additional eight weeks.

In this study, the main goal is to confirm the findings of our earlier study. The investigators would also like to understand how the DASH/SRD changes the function of the heart and blood vessels during exercise and the activity of genes that could be involved in HFPEF.


Recruitment information / eligibility

Status Terminated
Enrollment 18
Est. completion date February 16, 2016
Est. primary completion date November 18, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Symptoms and/or signs of HFPEF in the past 12 months

- Most recent LVEF = 50% (contrast ventriculography, echocardiography, nuclear scintigraphy)

- Diastolic dysfunction on previous echocardiogram/catheterization or evidence of abnormal neurohormonal activation (B-type natriuretic peptide (BNP) = 100 pg/ml)

- History of systemic hypertension

- Willing to adhere to provided diet

Exclusion Criteria:

- NYHA Class IV heart failure symptoms

- Hospitalization for decompensated HF within past one month

- Uncontrolled hypertension (seated SBP = 180 or DBP = 110) at rest, on current antihypertensive regimen

- Changes in medical regimen for heart disease or hypertension within past 1 month, except diuretic dose adjustment (within past 1 week)

- Previous LVEF < 40%

- Primary exercise limitation due to severe pulmonary disease

- Uninterpretable echocardiographic windows

- Worse than moderate mitral or aortic stenosis or insufficiency.

- Baseline serum potassium level > 5.0 mmol/L or prior history of potassium > 6.0

- Serum calcium/phosphorus product > 50 at baseline

- Severe renal insufficiency (current estimated GFR < 30 ml/min)

- Severe anemia (Hgb < 9 g/dL)

- Severely uncontrolled diabetes mellitus (Hgb A1C > 10%)

- Non-hypertension related cause of HFPEF (e.g. amyloidosis, sarcoidosis, constrictive pericardial syndromes, primary hypertrophic or restrictive cardiomyopathy)

- Primary right ventricular failure

- Myocardial infarction or unstable angina, including new or worsening anginal syndrome, within the past three months

- Uncontrolled arrhythmia (including non rate-controlled atrial fibrillation)

- Terminal illness expected to result in death within six months

- Psychiatric disorder or dementia with potential to compromise dietary adherence

Study Design


Intervention

Behavioral:
DASH/sodium-restricted diet (DASH/SRD)
Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
Control Diet
The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

References & Publications (4)

Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD, Egan BM. Low-Sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. J Hum Hypertens. 2009 Dec;23(12):826-35. doi: 10.1038/jhh.2009.32. Epub 2009 Apr 30. — View Citation

Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010 Sep 7;56(11):845-54. doi: 10.1016/j.jacc.2010.03.077. — View Citation

Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, Rosenblum HR, Wells JM, Weder AB. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension. 2012 Nov;60(5):1200-6. doi: 10.1161/HYPERTENSIONAHA.112.202705. Epub 2012 Oct 1. — View Citation

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary F2-Isoprostanes The change from Baseline in Urinary F2-Isoptorstanes at Week 3, Week 6, and Week 14
Secondary 24-hour ambulatory blood pressure (mean and diurnal variation) The change from Baseline in 24-hour blood pressure at Week 3, Week 6, and Week 14
Secondary Carotid-femoral pulse wave velocity The change from Week 3 in Carotid-femoral pulse wave velocity at Week 6, and Week 14
Secondary Six minute walk test distance The change from Baseline in six minute walk test distance at Week 3, Week 6, and Week 14
Secondary Estimated glomerular filtration rate, serum potassium, serum calcium-phosphorus product The change from Baseline in estimated glomerular filtration rate, serum potassium, serum calcium-phosphorus distance at Week 3, Week 6, and Week 14
Secondary Echocardiographic ventricular systolic and diastolic function (resting), ventricular-vascular coupling (resting and during bicycle ergometer exercise) The change from Week 3 in Echocardiographic ventricular systolic and diastolic function (resting), ventricular-vascular coupling (resting and during bicycle ergometer exercise) at Week 6, and Week 14
Secondary Knowledge, skills and attitudes related to DASH/SRD Will be assessed using the Dietary Sodium Restriction and the PACE questionnaires Change from the screening visit in knowledge, skills and attitudes related to DASH/SRD to Week 6
Secondary Pro-oxidant and pro-inflammatory gene activation in peripheral mononuclear cells and venous endothelial cells The change from Baseline in Pro-oxidant and pro-inflammatory gene activation in peripheral mononuclear cells and venous endothelial cells at Week 3, Week 6, and Week 14
See also
  Status Clinical Trial Phase
Recruiting NCT02499601 - CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) N/A
Completed NCT02537041 - Non-invasive Evaluation of Myocardial Stiffness by Elastography N/A
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Withdrawn NCT00773084 - Aliskiren and Renin Inhibition in Diastolic Heart Failure N/A
Terminated NCT00293150 - Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure Phase 4
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Terminated NCT01778894 - Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart
Completed NCT04154878 - 2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
Recruiting NCT01599117 - A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF] Phase 3
Completed NCT01185067 - Physiological Effects of Grape Seed Extract in Diastolic Heart Failure Phase 1
Completed NCT03338374 - Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction N/A
Completed NCT02589977 - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Phase 4
Completed NCT02147613 - High Intensity Interval Exercise in Diastolic Heart Failure N/A
Terminated NCT00083772 - Use of Nesiritide in the Management of Acute Diastolic Heart Failure Phase 4
Completed NCT00303498 - A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure Phase 2
Terminated NCT02254382 - Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure N/A
Completed NCT00839228 - Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome Phase 2
Terminated NCT00662116 - Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) Phase 2
Completed NCT02084992 - A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure N/A
Completed NCT02916225 - High Intensity Interval Training Versus Moderate Continuous Training in Heart Failure With Preserved Ejection Fraction N/A